SMMT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

35.07

Margin Of Safety %

Put/Call OI Ratio

0.68

EPS Next Q Diff

-0.01

EPS Last/This Y

0.56

EPS This/Next Y

0.01

Price

16.56

Target Price

29.79

Analyst Recom

1.71

Performance Q

-9.79

Upside

-212.9%

Beta

-1.3

Ticker: SMMT

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	SMMT	15.73	1.00	0.04	63284
2026-03-10	SMMT	16.32	0.91	0.04	66810
2026-03-11	SMMT	16.07	0.85	0.09	69306
2026-03-12	SMMT	15.45	0.83	0.25	70098
2026-03-13	SMMT	15.46	0.83	0.25	70098
2026-03-17	SMMT	15.83	0.77	0.10	73338
2026-03-18	SMMT	15.6	0.75	0.29	74798
2026-03-19	SMMT	15.72	0.75	0.08	75299
2026-03-20	SMMT	15.51	0.74	0.22	75769
2026-03-23	SMMT	15.59	0.74	0.48	64602
2026-03-24	SMMT	15.53	0.73	0.38	66964
2026-03-25	SMMT	17.95	0.71	0.31	69115
2026-03-26	SMMT	17.28	0.66	0.04	74040
2026-03-27	SMMT	16.57	0.68	0.07	72980
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

14 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	SMMT	15.73	-225.6	668.8	-0.88
2026-03-10	SMMT	16.33	-225.6	670.6	-0.88
2026-03-11	SMMT	16.07	-225.6	689.4	-0.88
2026-03-12	SMMT	15.46	-225.6	699.3	-0.88
2026-03-13	SMMT	16.12	-225.6	665.9	-0.88
2026-03-17	SMMT	15.85	-225.6	695.4	-0.88
2026-03-18	SMMT	15.61	-225.6	690.5	-0.88
2026-03-19	SMMT	15.72	-225.6	680.0	-0.88
2026-03-20	SMMT	15.52	-225.6	723.6	-0.88
2026-03-23	SMMT	15.59	-225.6	721.9	-0.88
2026-03-24	SMMT	15.54	-225.6	723.1	-0.88
2026-03-25	SMMT	17.96	-225.6	664.2	-0.88
2026-03-26	SMMT	17.27	-226.1	681.0	-0.88
2026-03-27	SMMT	16.56	-226.1	698.3	-0.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

14 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-06	SMMT	0.20	11.89	36.77
2026-03-09	SMMT	0.20	11.89	36.77
2026-03-10	SMMT	0.20	11.89	36.77
2026-03-11	SMMT	0.20	11.89	33.67
2026-03-12	SMMT	0.09	11.89	33.67
2026-03-13	SMMT	0.09	11.89	33.67
2026-03-17	SMMT	0.09	11.90	33.67
2026-03-18	SMMT	0.09	11.90	33.67
2026-03-19	SMMT	0.09	11.90	33.67
2026-03-20	SMMT	0.09	11.90	33.67
2026-03-23	SMMT	0.09	11.85	33.67
2026-03-24	SMMT	0.09	11.85	33.67
2026-03-25	SMMT	0.09	11.85	35.07
2026-03-26	SMMT	0.09	11.85	35.07
2026-03-27	SMMT	0.09	11.85	35.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.22

Avg. EPS Est. Next Quarter

-0.22

Insider Transactions

0.09

Institutional Transactions

11.85

Beta

-1.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

55.1

Max Drawdown 5-Year %

-92

Target Price

29.79

P/E

Forward P/E

PEG

P/S

P/B

19.51

P/Free Cash Flow

EPS

-1.44

Average EPS Est. Cur. Y

-0.88

EPS Next Y. (Est.)

-0.87

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.78

Return on Equity vs Sector %

-191.2

Return on Equity vs Industry %

-174.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.14

EBIT Estimation

698.3

◆ SMMT Healthcare

$16.58

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

5/25

Volume

9/15

Valuation

12/20

TP/AR

1/10

Options

6/10

RSI

54.1

Range 1M

57.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

8/30

Estimates

0/20

Inst/Vol

5/15

Options

8/10

EPS Yr

19.2%

EPS NY

0.6%

52W%

12.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +79.7% upside

Quality

2/30

Valuation

12/30

Growth

4/25

Stability

7/10

LT Trend

5/5

Upside

+79.7%

Quality

Summit Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 265

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

SMMT

Latest News

—

Caricamento notizie per SMMT…

stock quote shares SMMT – Summit Therapeutics Inc Stock Price stock today

news today SMMT – Summit Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch SMMT – Summit Therapeutics Inc yahoo finance google finance

stock history SMMT – Summit Therapeutics Inc invest stock market

stock prices SMMT premarket after hours

ticker SMMT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: SMMT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y